solute carrier family 5 member 10Genealiases: SGLT-5 · SGLT5
Q-omics provides the consensus-scored SLC5A10 profile across patient tissues and cancer cell-line models. SLC5A10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC5A10 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, SLC5A10 RNA expression shows 15,625 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where SLC5A10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC5A10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC5A10 survival associations across molecular data types. SLC5A10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC5A10 RNA expression–survival associations across cancer types. High SLC5A10 expression shows unfavorable associations in LGG, MESO and SKCM, but favorable associations in KIRC, ESCA and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC5A10 RNA expression.
This table summarizes SLC5A10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC5A10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC5A10 shows lower tumor expression in KIRP, KICH and COAD and higher tumor expression in KIRC, BRCA and HNSC. The KIRP box plot shows higher SLC5A10 RNA expression in normal versus tumor tissue (log2 FC = −4.260, t-test p < 0.001).
This table shows molecular features associated with SLC5A10 in patient tissues and cancer cell lines. In patient samples, SLC5A10 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC5A10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
